NCT01902173: A reported trial by National Cancer Institute (NCI)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01902173 |
|---|---|
| Title | Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Oct. 8, 2013 |
| Completion date | May 16, 2018 |
| Required reporting date | May 16, 2019, midnight |
| Actual reporting date | May 13, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |